CCM: AI 评分 43/100 — AI 分析 (4月 2026)

Key Facts: Price: $4.80 AI Score: 43/100 Sector: Healthcare

公司概况

概要：

Concord Medical Services Holdings Limited, based in China, operates a network of radiotherapy and diagnostic imaging centers. The company offers a comprehensive suite of cancer treatment and diagnostic services, including radiotherapy, gamma knife radiosurgery, and diagnostic imaging. It also provides clinical support and equipment leasing, positioning it as an integrated oncology solutions provider.

CCM是做什么的？

Founded in 1997 and headquartered in Beijing, Concord Medical Services Holdings Limited operates a network of radiotherapy and diagnostic imaging centers across the People's Republic of China. The company has evolved into a comprehensive provider of cancer treatment solutions, operating through two primary segments: Network and Hospital. The Network segment focuses on providing radiotherapy and diagnostic imaging services through cooperative centers located within hospitals. These services include linear accelerator-based external beam radiotherapy, gamma knife radiosurgery, and diagnostic imaging using computed tomography scanners. Concord Medical also offers clinical support services, such as developing treatment protocols, organizing joint diagnoses, and assisting with the recruitment and compensation of medical personnel. The Hospital segment involves the operation of specialty cancer hospitals, offering a full spectrum of cancer treatments, including radiotherapy, diagnostic imaging, chemotherapy, and surgery. As of December 31, 2021, Concord Medical operated 16 cooperative centers in 13 hospitals. In addition to its core services, the company engages in radiotherapy and diagnostic equipment leasing, management services, premium cancer and proton treatment services, teleconsultation, and medical information technology services. It also sells medical equipment.

CCM的投资论点是什么？

Concord Medical Services Holdings Limited presents a complex investment case. The company's negative profit and gross margins (-44.6% and -11.4% respectively) indicate significant challenges in achieving profitability. The company's beta of -1.23 suggests an inverse correlation to the market, which may appeal to investors seeking diversification. Growth catalysts include expanding its network of cooperative centers and hospitals, and increasing adoption of advanced radiotherapy techniques. However, investors should closely monitor the company's ability to improve its financial performance and navigate the regulatory landscape in China's healthcare sector.

CCM在哪个行业运营？

Concord Medical Services Holdings Limited operates within China's growing healthcare market, specifically in the oncology sector. The demand for cancer treatment services is increasing due to an aging population and rising cancer rates. The competitive landscape includes both domestic and international players offering similar radiotherapy and diagnostic imaging services. Concord Medical differentiates itself through its network of cooperative centers and hospitals, providing a comprehensive suite of cancer treatment solutions. The industry is subject to regulatory oversight and technological advancements, requiring companies to adapt to changing market dynamics.

Medical - Care Facilities

Healthcare

CCM有哪些增长机遇？

Expansion of Cooperative Centers: Concord Medical has the opportunity to expand its network of cooperative centers within existing and new hospitals across China. This expansion can increase its geographic reach and patient access, driving revenue growth. The market for radiotherapy services in China is projected to grow, driven by increasing cancer incidence and government support for advanced medical technologies. A realistic timeline for adding 2-3 centers per year over the next 3-5 years could significantly boost revenue.
Adoption of Advanced Radiotherapy Techniques: The company can drive growth by promoting the adoption of advanced radiotherapy techniques, such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT). These techniques offer more precise and effective cancer treatment, attracting patients seeking advanced care. The market for advanced radiotherapy is growing rapidly, with increasing demand from both patients and physicians. Concord Medical can invest in training and technology to become a leader in this area.
Development of Specialty Cancer Hospitals: Concord Medical can further develop its specialty cancer hospitals, offering a full range of cancer treatments, including radiotherapy, diagnostic imaging, chemotherapy, and surgery. This integrated approach can attract patients seeking comprehensive cancer care under one roof. The market for specialty cancer hospitals is growing, driven by increasing demand for specialized cancer treatment services. The company can invest in expanding its hospital network and enhancing its service offerings.
Strategic Partnerships: Concord Medical can pursue strategic partnerships with other healthcare providers, research institutions, and technology companies to expand its service offerings and market reach. These partnerships can provide access to new technologies, expertise, and patient networks. The healthcare industry is increasingly collaborative, with companies forming partnerships to leverage each other's strengths. Concord Medical can explore partnerships with companies specializing in areas such as genomics, immunotherapy, and artificial intelligence.
Teleconsultation and Medical IT Services: The company can leverage teleconsultation and medical IT services to improve patient access and streamline operations. Teleconsultation can enable remote consultations with specialists, while medical IT services can improve data management and treatment planning. The market for telemedicine and medical IT is growing rapidly, driven by increasing adoption of digital health technologies. Concord Medical can invest in developing its teleconsultation platform and medical IT infrastructure.

Operates a network of 16 cooperative centers based in 13 hospitals as of December 31, 2021.
Offers a range of radiotherapy services, including linear accelerator external beam radiotherapy and gamma knife radiosurgery.
Provides diagnostic imaging services, including computed tomography (CT) scans.
Offers clinical support services, such as developing treatment protocols and organizing joint diagnoses.
Operates specialty cancer hospitals providing radiotherapy, diagnostic imaging, chemotherapy, and surgery.

CCM提供哪些产品和服务？

Operates a network of radiotherapy and diagnostic imaging centers in China.
Provides linear accelerator external beam radiotherapy.
Offers gamma knife radiosurgery for head and body tumors.
Performs diagnostic imaging services using CT scanners.
Provides clinical support services to doctors.
Offers radiotherapy and diagnostic equipment leasing.
Operates specialty cancer hospitals offering comprehensive cancer treatments.

CCM如何赚钱？

Generates revenue from radiotherapy and diagnostic imaging services provided through its network of cooperative centers.
Earns revenue from the operation of specialty cancer hospitals, offering a range of cancer treatments.
Derives income from leasing radiotherapy and diagnostic equipment to hospitals.
Receives fees for providing management services to hospitals.
Generates revenue from the sale of medical equipment.

Patients seeking radiotherapy and diagnostic imaging services.
Hospitals that partner with Concord Medical to establish cooperative centers.
Hospitals that lease radiotherapy and diagnostic equipment from Concord Medical.
Patients seeking comprehensive cancer treatment at Concord Medical's specialty cancer hospitals.

Established network of cooperative centers and hospitals across China.
Comprehensive suite of cancer treatment and diagnostic services.
Expertise in radiotherapy and diagnostic imaging.
Strong relationships with hospitals and medical professionals.

什么因素可能推动CCM股价上涨？

Ongoing: Expansion of the network of cooperative centers and specialty cancer hospitals.
Ongoing: Increasing adoption of advanced radiotherapy techniques, such as IMRT and SBRT.
Ongoing: Strategic partnerships with other healthcare providers and technology companies.

CCM的主要风险是什么？

Ongoing: Negative profit margin and gross margin, indicating financial challenges.
Potential: Changes in government regulations and healthcare policies in China.
Potential: Competition from other radiotherapy and diagnostic imaging providers.
Potential: Technological advancements that could render existing equipment obsolete.

CCM的核心优势是什么？

Established network of radiotherapy and diagnostic imaging centers in China.
Comprehensive suite of cancer treatment services.
Expertise in advanced radiotherapy techniques.
Strong relationships with hospitals and medical professionals.

CCM的劣势是什么？

Negative profit margin and gross margin.
Reliance on cooperative centers within hospitals.
Exposure to regulatory risks in China's healthcare sector.
Limited geographic diversification.

CCM有哪些机遇？

Expansion of cooperative centers and specialty cancer hospitals.
Adoption of advanced radiotherapy techniques.
Strategic partnerships with other healthcare providers.
Growth in China's healthcare market.

CCM面临哪些威胁？

Competition from other radiotherapy and diagnostic imaging providers.
Changes in government regulations and healthcare policies.
Technological advancements that could render existing equipment obsolete.
Economic downturn in China.

CCM的竞争对手是谁？

Aditxt, Inc. — Focuses on immune monitoring and therapies. — (ADTX)
Black Diamond Therapeutics, Inc. — Develops small molecule, tumor-agnostic therapies. — (BACK)
Celularity, Inc. — Develops placental-derived cell therapies. — (CELU)
Hepion Pharmaceuticals, Inc. — Focuses on developing therapies for liver diseases. — (HEPA)
In Vitro Fertilization Market — Offers fertility treatment services. — (IVF)

Key Metrics

Price: $4.80 (+12.41%)
Volume: 47,615
MoonshotScore: 43/100

Company Profile

CEO: Jianyu Yang
Headquarters: Beijing, CN
Employees: 595
Founded: 2009

AI Insight

Concord Medical Services Holdings Limited operates a network of radiotherapy and diagnostic imaging centers in China. They offer a range of services including radiotherapy, diagnostic imaging, and clinical support.

常见问题

What does Concord Medical Services Holdings Limited do?

Concord Medical Services Holdings Limited operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company provides a range of services, including linear accelerator external beam radiotherapy, gamma knife radiosurgery, and diagnostic imaging services using computed tomography scanners. It also operates specialty cancer hospitals, offering a full spectrum of cancer treatments, including radiotherapy, diagnostic imaging, chemotherapy, and surgery. Concord Medical also provides clinical support services, equipment leasing, and teleconsultation services.

What do analysts say about CCM stock?

There is no analyst consensus available in the provided data. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. Key valuation metrics to consider include the company's market capitalization, price-to-earnings ratio, profit margin, and gross margin. Growth considerations include the company's ability to expand its network of cooperative centers and hospitals, and to increase adoption of advanced radiotherapy techniques.

What are the main risks for CCM?

The main risks for Concord Medical Services Holdings Limited include its negative profit margin and gross margin, indicating financial challenges. The company is also exposed to regulatory risks in China's healthcare sector, as well as competition from other radiotherapy and diagnostic imaging providers. Technological advancements could also render existing equipment obsolete. Additionally, as an ADR, the company is exposed to currency risk related to fluctuations in the exchange rate between the U.S. dollar and the Chinese Yuan.